Heart failure & cardiomyopathies
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry
Authors' conclusion
These results provide prospective evidence for incorporating cardiac magnetic resonance and NT-proBNP in the evaluation of patients with hypertrophic cardiomyopathy.
Study context
- Population
- Patients with hypertrophic cardiomyopathy, enrolled April 1, 2014, to April 7, 20172,698 (98%) analysable
- Participants
- 2,750 patients
- Outcome
- Time to first HCM-related death, nonfatal sustained VA requiring cardioversion or defibrillation, or LV assist device implant or heart transplant (adjudicated composite)
Methodological detailsmulticentre, 44 sites in North America and Europe
- Multicentre
- 44 sites in North America and Europe
Main finding
As reported in the abstract
Primary composite (HCM-related death, nonfatal sustained VA, LV assist device or heart transplant): multivariable predictors
Hazard ratio (95% CI)P value
LGE%per 10-unit increase
1.86(1.58–2.20)
P < 0.001LV mass indexper 10-unit increase
1.09(1.01–1.17)
P = 0.03LV end-systolic volume indexper 10-unit increase
1.28(1.12–1.46)
P < 0.001History of heart failure at study entry
2.89(1.75–4.77)
P < 0.001Log NT-proBNPper log unit
1.41(1.17–1.70)
P < 0.001Each row per its own increment, as printed
- C index for all
- 0.77
- LGE ≥9% of left ventricular (LV) mass substantially increased primary composite event rate
- P = 0.001
Observational data: associations, not effects.
Secondary outcomes
SCD and nonfatal VA composite (69 patients)
- Model included LGE%, LV mass index, LVEF and log(NT-proBNP); C index
- 0.76
Original publication
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry. JAMA. Published 9 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →